F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comSanofi Consumer Healthcare India Ltd is one of the leading pharmaceutical and consumer healthcare companies in India. The company is a subsidiary of the global healthcare leader Sanofi S.A., headquartered in France. Known for trusted over-the-counter (OTC) brands like Combiflam, Allegra, and Digene, Sanofi Consumer Healthcare has a strong presence across wellness, pain relief, allergy, and digestive health categories.
In this article, we’ll explore Sanofi Consumer Healthcare India Ltd’s share price target from 2025 to 2030, including its business fundamentals, shareholding pattern, and year-wise forecast based on current performance indicators.
| Detail | Value |
|---|---|
| Open | ₹4,601.30 |
| Previous Close | ₹4,621.70 |
| Day’s High | ₹4,750.00 |
| Day’s Low | ₹4,562.00 |
| 52-Week High | ₹5,894.50 |
| 52-Week Low | ₹4,537.45 |
| Market Capitalization | ₹10,740 Crore |
| Volume | 3,970 |
| Value (Lacs) | 185.14 |
| VWAP | ₹4,645.22 |
| Beta (Volatility) | 0.14 |
| Face Value | ₹10 |
| Book Value per Share | ₹99.71 |
| Dividend Yield | 1.18% |
| All-Time High | ₹5,894.50 |
| All-Time Low | ₹4,211.55 |
Sanofi Consumer Healthcare India Ltd is a major player in India’s over-the-counter (OTC) and wellness industry. The company focuses on manufacturing and marketing medicines and healthcare products that improve the quality of life of millions of consumers.
The company’s flagship brands include:
Combiflam – one of India’s most popular pain relief medicines.
Allegra – a trusted antihistamine for allergy management.
Digene – a household name for digestive health.
DePura and Avil – key products in the vitamins and allergy segments.
With an established distribution network and a strong portfolio of legacy brands, Sanofi Consumer Healthcare is positioned as a stable and defensive stock in the healthcare sector.
Strong global brand backing from Sanofi S.A.
Presence across multiple fast-growing categories: pain relief, digestion, vitamins, and allergy.
Focused on innovation and consumer wellness products.
Maintains a low beta (0.14), indicating very low volatility.
Regular dividend payouts with a 1.18% yield, reflecting financial stability.
Expanding rural and urban market penetration through digital and retail initiatives.
| Investor Type | Holding (%) |
|---|---|
| Promoters | 71.27% |
| Mutual Funds | 12.85% |
| Retail & Others | 8.59% |
| Other Domestic Institutions | 4.04% |
| Foreign Institutions | 3.24% |
The high promoter holding of over 70% demonstrates strong confidence from the parent company, while mutual fund participation highlights institutional trust in Sanofi’s long-term growth story.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 4,800 | 5,000 |
| 2026 | 5,100 | 5,400 |
| 2027 | 5,450 | 5,800 |
| 2028 | 5,900 | 6,200 |
| 2029 | 6,300 | 6,700 |
| 2030 | 6,800 | 7,200 |
These projections are based on Sanofi’s consistent financial performance, stable dividend record, and the growing demand for OTC health products in India.
In 2025, the stock is expected to remain steady due to stable earnings and increasing demand for its core healthcare products.
Why:
Strong brand loyalty for flagship products like Combiflam and Digene.
Increasing consumer focus on self-care and wellness.
Steady dividend payout and low market volatility.
Investment Advice: Ideal for conservative investors looking for stable returns.
By 2026, the company may see growth driven by product diversification and pricing improvements.
Why:
Expansion of OTC portfolio and introduction of new variants.
Cost efficiency from optimized manufacturing operations.
Growth in domestic and export sales.
Investment Advice: Suitable for long-term investors; continue accumulating on dips.
In 2027, Sanofi Consumer Healthcare could gain further momentum due to rising urban demand and digital sales expansion.
Why:
E-commerce penetration boosting sales of OTC products.
Strategic marketing and brand repositioning.
Consistent profitability and strong cash reserves.
Investment Advice: Hold for long-term wealth creation and regular dividends.
By 2028, the company may record all-time high valuations as consumer health awareness continues to rise across India.
Why:
Growing demand for preventive healthcare solutions.
High return on equity (ROE) due to premium pricing.
Strong performance in allergy and digestive health categories.
Investment Advice: Continue long-term holding; expect steady compounding returns.
The year 2029 may witness sustained growth due to strategic innovations and consistent dividend distributions.
Why:
Brand reinvestment in research and new product launches.
Efficient supply chain and distribution network expansion.
Strengthened presence in Tier-2 and Tier-3 cities.
Investment Advice: Good defensive stock for maintaining portfolio stability.
By 2030, Sanofi Consumer Healthcare India Ltd could reach new highs, supported by consistent growth, solid brand positioning, and expanding market share.
Why:
Rising consumer spending on healthcare.
Strong leadership from global parent Sanofi.
Increasing penetration of self-care products across India.
Investment Advice: Excellent long-term investment for investors seeking stable and reliable returns from the healthcare sector.
Yes. Sanofi Consumer Healthcare India Ltd is a stable and fundamentally strong company with low volatility and consistent dividends. It’s a suitable choice for investors seeking steady, defensive exposure to India’s growing healthcare and wellness sector.
Backed by a global healthcare leader (Sanofi S.A.)
Consistent dividend payouts.
Low volatility stock ideal for risk-averse investors.
Increasing market demand for OTC health products.
Competition from domestic and multinational FMCG players.
Regulatory changes in pharmaceutical pricing.
Dependency on limited blockbuster brands for major revenue.
Always review quarterly results and seek advice from a certified financial expert before investing.
Sanofi Consumer Healthcare India Ltd stands out as one of India’s most reliable healthcare companies, backed by global expertise and strong brand equity. With a current market price near ₹4,600 and a strong dividend track record, the company is poised for steady growth in the coming years.
By 2030, analysts expect the stock to potentially reach ₹7,200, driven by growing demand for OTC and wellness products. For investors aiming for a mix of safety, moderate growth, and consistent dividends, Sanofi Consumer Healthcare can be an excellent addition to a long-term portfolio.
1. What is the current share price of Sanofi Consumer Healthcare India Ltd?
As of October 2025, the share price is around ₹4,621.70.
2. What is the 52-week high and low of Sanofi Consumer Healthcare?
The 52-week high is ₹5,894.50, and the low is ₹4,537.45.
3. What is the share price target of Sanofi Consumer Healthcare for 2025?
The 2025 target is expected between ₹4,800 and ₹5,000.
4. What will be the Sanofi Consumer Healthcare share price target for 2030?
By 2030, the share price could reach between ₹6,800 and ₹7,200.
5. Is Sanofi Consumer Healthcare a good long-term investment?
Yes, it is a stable, dividend-paying company with steady growth potential.
6. What is the market capitalization of Sanofi Consumer Healthcare?
The company’s market cap stands at approximately ₹10,740 crore.
7. What is the face value of Sanofi Consumer Healthcare shares?
The face value of each share is ₹10.
8. What is the dividend yield of Sanofi Consumer Healthcare?
The dividend yield is approximately 1.18%.
9. Who are the major shareholders in Sanofi Consumer Healthcare India Ltd?
Promoters hold 71.27%, followed by mutual funds (12.85%) and retail investors (8.59%).
10. What are Sanofi Consumer Healthcare’s top products?
Combiflam, Allegra, Digene, and DePura are among its top-performing brands.
Disclaimer: This article is for educational purposes only and not investment advice. Please consult a certified financial advisor before making any investment decisions.
Register & Login